A real world study of apatinib treatment in gastric cancer: Current status and clinical benefit

作者：Guoping Sun, Dongni Li, Zhenfei Ning, Yifu He, Jun Chang, Fan Zhang, Chenyan Jiang, Y. Cheng, Liming Xia, Bing Hu, Changjun Yu, Z. Wang, D. Wang, Ge Wang, Yong Zhao, Jiaqi Wang, Hui Liang, Maoming Xiong, Wesley Peng, H. Qian · 发表于：Annals of Oncology · 年份：2018 · DOI：10.1093/annonc/mdy282.067 · 被引用次数：1 · 研究领域：Gastric Cancer Management and Outcomes、Cholangiocarcinoma and Gallbladder Cancer Studies、Metastasis and carcinoma case studies

Background: Apatinib, a small molecule VEGFR TKI, has been approved in the treatment of advanced or metastatic gastric cancer (GC) in China. We performed a real world study to observe the current status, efficacy and safety of apatinib treatment in clinical practice, and preliminarily define patients (pts) who could benefit from apatinib.